[ET Net News Agency, 24 September 2021] Akeso, Inc. (09926) said the National Medical
Products Administration (the NMPA) of the People's Republic of China (China) has
officially accepted the new drug application for the world's first-in-class Cadonilimab
(PD1/CTLA-4 bi-specific antibody, research and development code: AK104) for the treatment
of relapsed or metastatic cervical cancer, which has received priority review.
Cadonilimab, independently developed and manufactured by the company, is the first PD-1
based bispecific antibody drug in the world to submit new drug application. Cadonilimab is
the second innovative antibody drug independently developed by the company to submit the
new drug application and the fifth new drug application submitted by the Company in China
and in the United States. (RC)